Entecavir With or Without Pegylated Interferon α-2b in Children Aged 3-6 Years With Immune-Active Chronic Hepatitis B

This study aims to evaluate the efficacy and safety of entecavir monotherapy versus sequential entecavir plus pegylated interferon α-2b in achieving functional cure in immune-active, HBeAg-positive children aged 3-6 years with chronic hepatitis B.

NCT Number	NCT07345611
Lead Sponsor	Qing-Lei Zeng Collaborators: Henan Provincial People's Hospital, Luoyang Central Hospital, Xuchang Central Hospital, Luohe Central Hospital, Yongcheng People's Hospital, Sanmenxia Central Hospital, The Third Affiliated Hospital of Henan Medical University, Weishi County People's Hospital, The Sixth People's Hospital of Zhengzhou, The First Affiliated Hospital of Zhengzhou University, Shangcheng County People's Hospital, The First Affiliated Hospital of Henan Polytechnic University, Nanyang Central Hospital
Conditions	Hepatitis B Virus Infection, Children, Chronic Hepatitis B
Enrollment	60 participants
Start Date	2026-01-11
Primary Completion	2030-12-31 (estimated)
Study Completion	2030-12-31 (estimated)
Updated on ClinicalTrials.gov	2026-01-16